Overview

Myrcludex B in Combination With Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone in Patients With Chronic Viral Hepatitis B With Delta-agent

Status:
Completed

Trial end date:
2020-10-30

Target enrollment:

Participant gender:

Summary

Randomised, Comparative, Parallel-Arm Study to Assess Efficacy and Safety of Myrcludex B in Combination with Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone in Patients with Chronic Viral Hepatitis B with Delta-agent

Phase:

Phase 2

Details

Lead Sponsor:

Hepatera Ltd.

Treatments:

Interferon alpha-2
Interferon-alpha
Peginterferon alfa-2a
Tenofovir